Influence of lipid profile and statin administration on arterial stiffness in renal transplant recipients.
arterial stiffness
hyperlipidemia
kidney transplantation
statin
Journal
Cardiology journal
ISSN: 1898-018X
Titre abrégé: Cardiol J
Pays: Poland
ID NLM: 101392712
Informations de publication
Date de publication:
2022
2022
Historique:
received:
13
12
2019
accepted:
15
02
2020
pubmed:
25
4
2020
medline:
14
4
2022
entrez:
25
4
2020
Statut:
ppublish
Résumé
Hyperlipidemia is one of the major risk factors for developing a cardiovascular disease (CVD) and it is a frequent post-transplant complication, occurring in up to 60% of the renal transplant recipients (RTRs). Lipid lowering therapy with HMG-CoA reductase inhibitors (statins) is generally recommended and may reduce the overall cardiovascular risk. The aim of this study was to evaluate the lipid profile, statin administration and their relationship with arterial stiffness parameters in RTRs. Three hundred and forty-four stable RTRs (62.5% male) transplanted between 1994 and 2018 were randomly enrolled to the study. The following parameters of arterial stiffness was measured in each patient: ankle brachial index, carotid femoral pulse wave velocity (baPWV left and right, cfPWV) and pulse pressure (PP right and left). The study group was divided based on the use statins: 143 (41.6%) and 201 (58.4%). RTRs were qualified to the statin (+) and the statin (-) group, respectively. In the statin (+) as compared to statin (-) group there were more patients with a CVD (32.9% vs. 14.9%) and diabetes (25.2% vs. 14.4%). In the whole study group, CVD was associated with a significant increase of both baPWV and cfPWV as well as PP (8.5 mmHg). There were significant differences in arterial stiffness parameters (baPWV, cfPWV, PP) between the statin (+) and the statin (-) group. Arterial stiffness was increased in RTRs with CVD and hyperlipidemia. The control of hyperlipidemia was poor in RTRs.
Sections du résumé
BACKGROUND
Hyperlipidemia is one of the major risk factors for developing a cardiovascular disease (CVD) and it is a frequent post-transplant complication, occurring in up to 60% of the renal transplant recipients (RTRs). Lipid lowering therapy with HMG-CoA reductase inhibitors (statins) is generally recommended and may reduce the overall cardiovascular risk. The aim of this study was to evaluate the lipid profile, statin administration and their relationship with arterial stiffness parameters in RTRs.
METHODS
Three hundred and forty-four stable RTRs (62.5% male) transplanted between 1994 and 2018 were randomly enrolled to the study. The following parameters of arterial stiffness was measured in each patient: ankle brachial index, carotid femoral pulse wave velocity (baPWV left and right, cfPWV) and pulse pressure (PP right and left). The study group was divided based on the use statins: 143 (41.6%) and 201 (58.4%). RTRs were qualified to the statin (+) and the statin (-) group, respectively.
RESULTS
In the statin (+) as compared to statin (-) group there were more patients with a CVD (32.9% vs. 14.9%) and diabetes (25.2% vs. 14.4%). In the whole study group, CVD was associated with a significant increase of both baPWV and cfPWV as well as PP (8.5 mmHg). There were significant differences in arterial stiffness parameters (baPWV, cfPWV, PP) between the statin (+) and the statin (-) group.
CONCLUSIONS
Arterial stiffness was increased in RTRs with CVD and hyperlipidemia. The control of hyperlipidemia was poor in RTRs.
Identifiants
pubmed: 32329037
pii: VM/OJS/J/65663
doi: 10.5603/CJ.a2020.0063
pmc: PMC9007483
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
263-271Références
Nephrol Dial Transplant. 2001 May;16(5):1047-52
pubmed: 11328915
Curr Opin Lipidol. 2015 Jun;26(3):195-9
pubmed: 25887677
Hypertension. 2004 Aug;44(2):186-90
pubmed: 15238570
Clin Exp Hypertens. 2018;40(7):601-608
pubmed: 29420075
J Am Soc Nephrol. 2011 Jul;22(7):1335-41
pubmed: 21566054
Ren Fail. 2003 May;25(3):411-7
pubmed: 12803504
Diab Vasc Dis Res. 2019 Jan;16(1):38-46
pubmed: 30328360
J Hum Hypertens. 2016 Jan;30(1):46-52
pubmed: 25810068
Transplantation. 2001 Jul 27;72(2):223-7
pubmed: 11477342
Eur Heart J. 2006 Nov;27(21):2588-605
pubmed: 17000623
Kidney Int Suppl. 2010 Dec;(119):S71-5
pubmed: 21116322
Am J Transplant. 2005 Jun;5(6):1576
pubmed: 15888073
Transplantation. 2014 Jun 27;97(12):1266-71
pubmed: 24521776
Transplantation. 2017 Oct;101(10):2612-2620
pubmed: 28333860
Transplant Proc. 2000 May;32(3):622-5
pubmed: 10812143
Lancet. 2011 Oct 15;378(9800):1419-27
pubmed: 22000138
Am J Kidney Dis. 2002 Sep;40(3):638-43
pubmed: 12200817
Nephrol Dial Transplant. 2014 Feb;29(2):232-9
pubmed: 24084326
Nephron Clin Pract. 2009;111(3):c159-66
pubmed: 19182491
Front Cardiovasc Med. 2019 May 24;6:67
pubmed: 31179288
J Am Soc Nephrol. 2008 Apr;19(4):798-805
pubmed: 18235095
Transplant Proc. 2018 Jul - Aug;50(6):1829-1833
pubmed: 30056909
Transplant Proc. 2007 Sep;39(7):2259-63
pubmed: 17889157
Cochrane Database Syst Rev. 2014 Jan 28;(1):CD005019
pubmed: 24470059
Ann Intern Med. 2013 Jun 4;158(11):825-30
pubmed: 23732715